Overview

Subjects With Open-angle Glaucoma, Pseudoexfoliative Glaucoma, or Ocular Hypertension Naïve to Medical and Surgical Therapy, Treated With Two Trabecular Micro-bypass Stents (iStent Inject) or Travoprost

Status:
Unknown status

Trial end date:
2018-06-01

Target enrollment:
0

Participant gender:
All

Summary

Evaluation of the intraocular pressure (IOP) lowering effect of two iStent inject devices versus medical therapy in eyes of subjects with primary open-angle glaucoma, pseudoexfoliative glaucoma, or ocular hypertension naïve to medical and surgical therapy.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Glaukos Corporation

Treatments:

Travoprost

Criteria

Inclusion Criteria:

- Phakic study eye

- IOP ≥ 21 mmHg and ≤ 40 mmHg at the screening visit (subjects with OHT require a second
screening IOP measurement

Exclusion Criteria:

- Aphakic or pseudophakic eyes (AC-IOLs or PC-IOLs)

- Previous usage of topical prostaglandin analogues or prior medical therapy for
glaucoma